AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Still some way to go...
Upside 176%
Price (€) 3.64
Market Cap (€M) 132
Perf. 1W: -9.45%
Perf. 1M: -23.4%
Perf. 3M: 5.51%
Perf Ytd: 10.5%
10 day relative perf. to stoxx600: -21.4%
20 day relative perf. to stoxx600: -22.5%
Target Change05/09/2018

On its way to reaching the market

Change in Target Price€ 17.8 vs 16.1+10.5%

Change in EPS2018 : € -0.94 vs -0.36ns
2019 : € -0.79 vs -0.06ns

We have fine-tuned our numbers in the back of the group’s latest comments as well as integrating the new NTE to be developed (Terbutaline) instead of Apomorphine which is now on stand-by. This said, short-term numbers have little meaning (other than the group’s cash-burn) since first sales should be booked in FY20.

Change in NAV€ 19.0 vs 18.2+4.78%

We have adjusted our numbers to take into account Terbutaline, the new therapeutic entity the group expects to develop alongside the six previous ones (already in our numbers). Some minor short-term changes have also impacted current net debt.

Change in DCF€ 24.9 vs 21.5+16.2%

Our DCF valuation goes up quite significantly after we integrated Terbutaline and fine-tuned our numbers (volumes and prices) for the other NTEs the group plans to market.


04 Feb 19 Financing issue
Some extra non-dilutive financing

24 Dec 18 EPS change
Adjustment in the number of shares

28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

27 Sep 18 Earnings/sales releases
H1 18: insignificant; some more time needed to ...

05 Sep 18 Target Change
On its way to reaching the market